- JPMorgan named Sri Kosaraju Global Chair of Investment Banking to strengthen its healthcare franchise.
- Kosaraju, a former JPMorgan healthcare banker and recent Inscripta CEO, will be based in San Francisco.
- He will report to Filippo Gori and John Simmons, co-heads of global banking.
- The hire extends JPMorgan’s recent investment-banking leadership buildout amid intensifying healthcare dealmaking competition.
Read More
On January 7, 2026, JPMorgan Chase announced it has appointed Sri Kosaraju as Global Chair of Investment Banking, specifically to lead enhancements in the firm’s healthcare industry vertical. Kosaraju returns to JPMorgan from Inscripta, where he recently served as Chief Executive Officer, after a 16-year prior career at JPMorgan, during which he helped build its healthcare franchise. He will be based in San Francisco and will report to Filippo Gori and John Simmons, who jointly head global banking for JPMorgan.
This appointment is strategically significant for several reasons. First, it underscores the growing importance of the healthcare sector within investment banking at large, and specifically for JPMorgan. The banking landscape over 2025 has seen elevated M&A, IPOs and sector-specific hiring, particularly in healthcare, as firms vie to capture deal flow in innovation and biotech.
Second, JPMorgan’s move follows a pattern of aggressive talent acquisition and internal restructuring. The bank has poached senior bankers from competitors, expanded its leadership in infrastructure banking, and elevated internal chairs to align with revived M&A activity. This is consistent with its goal to deepen its global banking footprint and client coverage.
Third, placing Kosaraju in San Francisco has tactical implications. Healthcare innovators and biotech firms are heavily clustered on the U.S. West Coast; positioning leadership there allows for better proximity to clients and deal origination. Combined with Kosaraju’s prior experience across both biotech and healthcare ECM, this placement enhances JPMorgan’s ability to compete in that geography.
However, there are open questions. How will Kosaraju’s return and role overlap or interact with the recently appointed Jerry Lee, also Global Chair with a healthcare focus? What are the specific targets for deal volume or market share in healthcare that have prompted this leadership expansion? And how sustainable is the elevated level of deal activity anticipated in 2026, especially given macroeconomic pressures such as rates, regulatory risk, and innovation cycles?
Supporting Notes
- Sri Kosaraju will rejoin JPMorgan from Inscripta, where he served as CEO; he had previously worked at JPMorgan for 16 years, building its healthcare franchise.
- His appointment is to support the firm’s healthcare industry vertical and he will report to Filippo Gori and John Simmons, co-heads of global banking.
- Kosaraju will be based in San Francisco.
- JPMorgan has also recently hired Jerry Lee as Global Chair of Investment Banking with a healthcare focus, highlighting leadership expansion in the sector.
- The move comes amid heightened deal-making appetite, including active hiring from Goldman Sachs and Deutsche Bank in late 2025.
- Dealmaking activity is expected to remain strong in 2026 despite earlier turbulence in 2025.